Interesting BMRN Put And Call Options For August 15th

Analysis of BioMarin Pharmaceutical (BMRN) options identifies tactical strategies for yield enhancement, leveraging current implied volatilities of 37-38% against a 36% trailing actual volatility. Selling the $57.50 strike put, with a 57% chance of expiring worthless, offers a potential 3.91% premium yield (37.59% annualized) or a reduced cost basis of $55.25 if assigned. Concurrently, a covered call using the $60.00 strike, with a 58% chance of expiring worthless, could generate a 3.19% premium boost (30.64% annualized) or a 6.64% total return if shares are called away, presenting opportunities for incremental returns for investors.

Analysis

The derivatives market for BioMarin Pharmaceutical (BMRN) presents opportunities for tactical yield enhancement and strategic position entry, based on current options pricing. Analysis highlights two specific out-of-the-money contracts. For bullish investors seeking a position, selling the $57.50 strike put contract offers a premium of $2.25, effectively lowering the share acquisition cost basis to $55.25 from the current $58.00 price, should the stock be assigned. Alternatively, if the option expires worthless, which has a stated probability of 57%, the seller would realize a 3.91% return on cash collateral (37.59% annualized). For existing shareholders, a covered call strategy at the $60.00 strike could generate $1.85 in premium, providing a 3.19% return boost (30.64% annualized) if the option expires worthless (a 58% probability). If the shares are called away, the total return would be capped at 6.64%. A key observation is that the implied volatility of the options (37-38%) is slightly elevated compared to the trailing twelve-month actual volatility of 36%, suggesting option sellers are being compensated for a marginally higher expected price movement than has historically occurred.

Key Decisions for Investors

• Investors bullish on BMRN but seeking a lower entry point could consider selling the $57.50 cash-secured put to either acquire shares at an effective cost of $55.25 or generate a 3.91% return on collateral.
• Current BMRN shareholders could implement a covered call strategy by selling the $60.00 strike call to generate immediate income, but must accept a capped total return of 6.64% if the stock price appreciates beyond $60.00.
• Given that implied volatility (37-38%) is trading at a slight premium to historical volatility (36%), conditions appear moderately favorable for option-selling strategies, though this premium could diminish.
• Since this analysis is purely technical and based on options data, investors should supplement these strategies with a thorough review of BMRN's underlying business fundamentals before committing capital.